The N terminus (the first 11 residues) that is highly conserved across GIP, GLP-1 and GCG interacts with the lower half of the TMD pocket of the three receptors consisting of conserved residues such as L/Y 1.36b (hydrophobic with K10 P ), Q/Y 1.40b (hydrogen bond with K10 P ), Y 1.43b (stacking with F6 P ), Y 1.47b (hydrogen bond with Q3 P ), Q 3.37b (hydrogen bond with H1 P ), ECL2 (hydrogen bond with S8 P ), R 7.35b (salt bridge with D9 P ), I/L 7.43b (hydrophobic with Aib2 P ) and L 7.43b (hydrophobic with F6 P ) (Figs
Increased focus on quality and third-party testing
Thats where the real value might be hiding
Pharmaceuticals 15 , 855 (2022)
Human trials need to define the product, route, dose, comparator, outcomes, adverse-event collection, and follow-up before those claims can be tested reliably